TrippBio, Inc.

TrippBio is developing a new, therapeutic application of an FDA-approved drug with a high probability to be proven safe and efficacious in the treatment and prevention of the SARS-CoV-2 virus that causes COVID-19.

Login to favorite a company

Visit SEC Page

Most Recent Valuation:

$5,255,840.00

Legal Name:

Founded:

State of HQ:

TrippBio, Inc

5/1/2020

Company Description

Employees:

Funding Summary

Number of funding rounds

1 Total amount raised

$185,796

Round name	End date	Raised	Status	Type	Investment minimum	Valuation	Valuation Cap	Price per share
TrippBio, Inc. Stock 1	01/29/2021	$185,796.00	closed	Common Stock	$100	$5,255,840		4

Screen Shot 2020-07-15 at 12.01.28 PM.pn

See round history

Round history

Round name	Perk description	Perk level (dollars)	Perk level (days)

Early Bird Perk history

View early bird perks, deal notes, company financials, and more

Join Crowdonomics+

Company notes

Type	Round name	Date Added	Date Updated	Notes

Financials (up to prior 4 years)

Revenue

COGS

Gross margin | (%)

Taxes

SG&A, other

Net income

Cash/Equivalents

Accounts Receiv

Other Assets

Assets

Short term debt

Long term debt

Equity/other liabilities

Gross margin, Other Assets, and Equity/other liabilities are derived from the financial statements of the company reported to the SEC. Assets = Liabilities + Equity, and no equity accounts nor accounts payable are reported to the SEC, hence the possibility for that amount to be either equity or a liability.